ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Stereotactic body radiation therapy (SBRT) with MRI-Linac in oligometastatic gynaecological cancer patients: a systematic review.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis review aims to provide a comprehensive overview of the current evidence on the use of MRI-guided SBRT for oligometastases in gynaecological cancers and its potential benefits. MATERIALS AND
methodsFollowing PRISMA guidelines, we conducted a systematic review to identify studies focusing on MRI-guided SBRT for oligometastatic gynaecological cancer. Inclusion criteria specified English-language studies that reported clinical outcomes and toxicity data. Data extraction included study design, tumour characteristics, type of MRI-Linac utilized, treatment protocols, clinical outcomes, and toxicity profiles.
resultsOf the 475 identified articles, three studies met the inclusion criteria, encompassing 45 patients with oligometastatic gynaecological cancers, predominantly ovarian, treated with 0.35-1.5 T MRI-Linac SBRT. Doses ranged from 30 to 50 Gy over five fractions. Focusing on actuarial outcome, all the patients were alive and maintained local control at 3 months from SBRT. The toxicity profile was available in all the studies, reporting only one Grade 3 event (gastro-intestinal), underscoring a favourable safety profile.
conclusionDespite some technical challenges, such as extended treatment times and limited MRI-Linac availability, MRI-guided SBRT appears to be a promising modality for oligometastatic ovarian cancer, potentially delaying the need for systemic therapy and chemotherapy line change. Larger studies are required to validate these findings and better establish the advantages relative to the use of this innovative approach.
Indexed as
Identifiers
42247114What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.